ZACKS:Ariad Pharmaceuticals had the Lowest Relative Performance in the Biotechnology Industry (ARIA, MNKD, BCRX, INSM, VNDA)
Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.
Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.
Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.
Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.
Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
Recent VNDA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:49:38 PM
- Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences • PR Newswire (US) • 05/07/2026 10:44:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:01:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:06:17 PM
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/06/2026 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:14 AM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/01/2026 08:35:00 PM
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • PR Newswire (US) • 04/29/2026 08:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/29/2026 08:08:37 PM
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence • PR Newswire (US) • 04/28/2026 11:12:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:35:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:50:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:48:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 09:23:06 PM
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors • PR Newswire (US) • 04/22/2026 09:13:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:38:37 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:37:04 PM
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines • PR Newswire (US) • 04/09/2026 03:02:00 PM
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists • PR Newswire (US) • 04/08/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:32 PM
- Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods • PR Newswire (US) • 03/19/2026 08:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:54:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:51:51 PM
